Resultats phase IIa NCX 4016 le 14 novembre

Phase IIa effectuée sur 40 patients atteints de diabète de type II, montrant que NCX 4016 était significativement plus efficace que l’aspirine et un placébo dans la prévention de l’activation plaquettaire induite par l’hyperglycémie aigüe.
(Les patients diabétiques présentent un risque accru de développer des complications cardiovasculaires dues à l’athérosclérose)

Date: 13-16 November 2005
Location: Dallas, TX, USA

Paolo Gresele of the University of Verona (Italy), and colleagues from the University of Perugia and NicOx Research Institute in Milan, are to present clinical trial results on NCX-4016 (NO-aspirin) in an oral abstract session on Monday morning. This compound is a nitric oxide-releasing non-steroidal anti-inflammatory drug under development by NicOx SA for the potential prevention of cardiovascular disorders. The data to be presented at AHA 2005 comes from a prospective randomized double-blind parallel group study that investigates the effects of treatment with NCX-4016, aspirin or a combination of the two on type 2 diabetes patients with induced hyperglycemia. The presenting scientists have previously shown that that acute, short-term, hyperglycemia enhances shear stress-induced platelet activation in type 2 diabetes patients; platelet hyperreactivity has been suggested as a potential mechanism of enhanced arterial thrombosis, and type 2 diabetes is associated with an increased risk of ischemic cardiovascular disease.


Aucun commentaire: